The GPR108 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the GPR108 gene. This product comprises a heterogeneous pool of NCI-H1975 cells harboring targeted disruptions in the GPR108 locus, providing a versatile model to investigate GPR108-dependent phenotypes without the constraints of clonal selection. The polyclonal format captures multiple independent editing events, making it suitable for functional genomics analyses in a lung adenocarcinoma background.
The host NCI-H1975 cell line is derived from a human non-small cell lung cancer (NSCLC) tumor and serves as a well-characterized model of lung adenocarcinoma. It harbors endogenous EGFR L858R and T790M mutations, which drive constitutive kinase activity and confer resistance to the tyrosine kinase inhibitor gefitinib. Consequently, NCI-H1975 cells are extensively used to study EGFR-driven oncogenic signaling and mechanisms of targeted therapy resistance.
GPR108 encodes an orphan G protein-coupled receptor (GPCR) of uncertain physiological function, though emerging data suggest a role in cell proliferation and intracellular signaling. As a GPCR, GPR108 is predicted to couple to heterotrimeric G proteins and ??-arrestin, modulating second messengers such as cAMP and calcium. In NCI-H1975 cells, GPR108 may engage the MAPK/ERK cascade (KRAS, MAPK1) and the PI3K/AKT/MTOR pathway (AKT1, MTOR), thereby influencing cell growth and survival decisions.
Disruption of GPR108 in the EGFR-mutant NCI-H1975 context creates a powerful tool to explore crosstalk between orphan GPCR signaling and aberrant receptor tyrosine kinase activity. Given the cell line??s dependence on EGFR-driven proliferation, knockout of GPR108 can unravel cooperative contributions that sustain the malignant phenotype or modulate drug sensitivity. The loss-of-function model is anticipated to impair any GPR108-mediated regulation of MAPK/ERK and PI3K/AKT pathway activity, offering insights into how orphan GPCRs may fine-tune oncogenic networks in lung adenocarcinoma.
These polyclonal knockout cells support diverse experimental approaches, including functional characterization of GPR108 in NSCLC, drug target validation, and identification of downstream signaling effectors. Common assays include Western blotting for phosphorylated MAPK/ERK and AKT, RT-qPCR for gene expression changes, cell proliferation assays (MTT, colony formation), apoptosis evaluation, flow cytometry for cell cycle analysis, and transcriptome profiling via RNA-seq. These methods collectively enable detailed phenotypic and molecular analyses. For further information or technical assistance, please contact Ascent Research.
